ZINBRYTA® (daclizumab)

Approved in Australia September 2016

ZINBRYTA is used for the management of relapsing forms of Multiple Sclerosis (MS). ZINBRYTA slows down the progression of physical disability in people with relapsing forms of MS and decreases the number of flare-ups (relapses) in patients with MS by reducing the inflammation in the central nervous system.


Patients Consumer Medicine Information (CMI)
Healthcare Professionals Product Information (PI)

The cause of MS is not yet known. MS affects the brain and spinal cord. In MS, the body’s immune system reacts against its own myelin (the ‘insulation’ surrounding nerve fibres). In relapsing forms of MS, people have ‘exacerbations’ from time to time (eg. blurred vision, weakness in the legs or arms, or loss of control of bowel or bladder function). They are followed by periods of recovery. Recovery may be complete or incomplete. If it is incomplete there is ‘progression of disability’.